Denali Therapeutics (DNLI) Interest Expenses (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Interest Expenses of $566000.0 for Q1 2026, down 80.48% year-over-year from $2.9 million in Q1 2025, and down 81.01% quarter-over-quarter from $3.0 million in Q4 2025.
Denali Therapeutics (DNLI) Interest Expenses (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Interest Expenses for 10 consecutive years, with $566000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 80.48% year-over-year to $566000.0; the TTM figure through Mar 2026 stood at $566000.0 (down 95.09% YoY), while the FY2025 annual figure was $14.1 million, down 97.11% from the prior year.
- Interest Expenses retreated to $566000.0 in Q1 2026 per DNLI's latest filing, from $3.0 million in the prior quarter.
- Across five years, Interest Expenses topped out at $48.1 million in Q2 2025 and bottomed at $566000.0 in Q1 2026.
- Historically, Interest Expenses has averaged $5.4 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2025 — Interest Expenses jumped 1585.63% — and 2026, when it plunged 80.48%.
- Denali Therapeutics' Interest Expenses stood at $3.0 million in 2022, then decreased by 6.78% to $2.8 million in 2023, then grew by 3.29% to $2.9 million in 2024, then gained by 3.29% to $3.0 million in 2025, then slumped by 81.01% to $566000.0 in 2026.
- Business Quant data shows DNLI's Interest Expenses at $566000.0 in Q1 2026, $3.0 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.00 Mn |
| Jun 30, 2026 | 3.00 Mn |
| Mar 31, 2026 | 566,000.00 |
| Mar 31, 2026 | 566,000.00 |
| Dec 31, 2025 | 2.98 Mn |
| Dec 31, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Sep 30, 2025 | 2.98 Mn |
| Jun 30, 2025 | 48.11 Mn |
| Jun 30, 2025 | 48.11 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Jun 30, 2024 | 2.85 Mn |
| Mar 31, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.79 Mn |